bluebird bio (BLUE) Stock Forecast, Price Target & Predictions
BLUE Stock Forecast
bluebird bio stock forecast is as follows: an average price target of $14.13 (represents a 2951.84% upside from BLUE’s last price of $0.46) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
BLUE Price Target
The average price target for bluebird bio (BLUE) is $14.13 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $5.00. This represents a potential 2951.84% upside from BLUE's last price of $0.46.
BLUE Analyst Ratings
According to 4 Wall Street analysts, bluebird bio's rating consensus is 'Hold'. The analyst rating breakdown for BLUE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (25.00%), 2 'Hold' (50.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
bluebird bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 22, 2022 | Gena Wang | Barclays | $5.00 | $5.83 | -14.16% | 979.91% |
| Mar 07, 2022 | David Nierengarten | Wedbush | $10.00 | $4.45 | 124.72% | 2059.83% |
| Nov 19, 2021 | Cory Kasimov | J.P. Morgan | $14.00 | $10.70 | 30.84% | 2923.76% |
| Nov 12, 2021 | Zhiqiang Shu | Berenberg Bank | $11.00 | $11.68 | -5.82% | 2275.81% |
| Nov 08, 2021 | Salveen Richter | Goldman Sachs | $10.00 | $10.70 | -6.54% | 2059.83% |
| Sep 13, 2021 | Joshua Schimmer | Evercore ISI | $25.00 | $11.84 | 111.15% | 5299.57% |
| Aug 10, 2021 | John Newman | Canaccord Genuity | $20.00 | $12.97 | 54.20% | 4219.65% |
| Aug 09, 2021 | Benjamin Burnett | Stifel Nicolaus | $18.00 | $11.76 | 53.06% | 3787.69% |
The latest bluebird bio stock forecast, released on Aug 22, 2022 by Gena Wang from Barclays, set a price target of $5.00, which represents a -14.16% decrease from the stock price at the time of the forecast ($5.83), and a 979.91% increase from BLUE last price ($0.46).
bluebird bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.46 | $0.46 | $0.46 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of bluebird bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to bluebird bio's last price of $0.46. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 25, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 25, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Aug 15, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 15, 2024 | Barclays | Underperform | Underperform | Hold |
| Aug 15, 2024 | Oppenheimer | Perform | Perform | Hold |
| Mar 27, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Mar 27, 2024 | Wedbush | Underperform | Underperform | Hold |
| Dec 15, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Jul 19, 2023 | Wedbush | Neutral | Buy | Upgrade |
| Jun 01, 2023 | Barclays | Equal-Weight | Overweight | Upgrade |
bluebird bio's last stock rating was published by RBC Capital on Sep 25, 2024. The company gave BLUE a "Underperform" rating, the same as its previous rate.
bluebird bio Financial Forecast
bluebird bio Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.39M | $6.89M | $2.38M | $62.00K | $71.00K | $1.52M | $1.95M | $-39.28M | $22.68M | $7.47M | $12.79M | $10.71M | $19.27M | $198.89M | $21.86M | $10.00M | $8.91M |
| Avg Forecast | $122.68M | $116.06M | $103.42M | $99.91M | $81.85M | $72.96M | $54.66M | $35.48M | $27.85M | $18.05M | $24.25M | $19.26M | $16.78M | $13.56M | $11.30M | $6.52M | $1.05M | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| High Forecast | $122.68M | $116.06M | $103.42M | $99.91M | $81.85M | $72.96M | $54.66M | $35.48M | $27.85M | $20.78M | $24.25M | $19.59M | $20.64M | $13.60M | $11.30M | $6.52M | $1.05M | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| Low Forecast | $122.68M | $116.06M | $103.42M | $99.91M | $81.85M | $72.96M | $54.66M | $35.48M | $27.85M | $12.61M | $24.25M | $18.93M | $11.63M | $13.52M | $11.30M | $6.52M | $1.05M | $1.07M | $824.17K | $187.50K | $5.08M | $37.21M | $16.28M | $11.55M | $14.65M | $24.32M | $76.46M | $7.58M | $9.17M | $11.38M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.61% | 0.36% | 0.06% | 0.07% | 1.84% | 10.37% | -7.73% | 0.61% | 0.46% | 1.11% | 0.73% | 0.79% | 2.60% | 2.88% | 1.09% | 0.78% |
bluebird bio's average Quarter revenue forecast for Dec 23 based on 7 analysts is $16.78M, with a low forecast of $11.63M, and a high forecast of $20.64M. BLUE's average Quarter revenue forecast represents a 35.44% increase compared to the company's last Quarter revenue of $12.39M (Sep 23).
bluebird bio EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-84.73M | $-85.30M | $-84.49M | $25.43M | $-88.18M | $-92.78M | $-119.33M | $-153.24M | $-210.63M | $-235.05M | $-199.67M | $-193.36M | $-187.50M | $-13.97M | $-192.28M | $-211.23M | $-193.33M |
| Avg Forecast | $-122.68M | $-116.06M | $-103.42M | $-99.91M | $-81.85M | $-72.96M | $-54.66M | $-35.48M | $-27.85M | $-18.05M | $-24.25M | $-85.33M | $-16.78M | $-13.56M | $-11.30M | $-91.26M | $-206.14M | $-1.07M | $-824.17K | $-97.61M | $-5.08M | $-37.21M | $-16.28M | $-195.69M | $-14.65M | $-24.32M | $-76.46M | $-210.02M | $-9.17M | $-11.38M |
| High Forecast | $-122.68M | $-116.06M | $-103.42M | $-99.91M | $-81.85M | $-72.96M | $-54.66M | $-35.48M | $-27.85M | $-12.61M | $-24.25M | $-68.26M | $-11.63M | $-13.52M | $-11.30M | $-73.01M | $-164.91M | $-1.07M | $-824.17K | $-78.09M | $-5.08M | $-37.21M | $-16.28M | $-156.55M | $-14.65M | $-24.32M | $-76.46M | $-168.02M | $-9.17M | $-11.38M |
| Low Forecast | $-122.68M | $-116.06M | $-103.42M | $-99.91M | $-81.85M | $-72.96M | $-54.66M | $-35.48M | $-27.85M | $-20.78M | $-24.25M | $-102.40M | $-20.64M | $-13.60M | $-11.30M | $-109.52M | $-247.37M | $-1.07M | $-824.17K | $-117.13M | $-5.08M | $-37.21M | $-16.28M | $-234.83M | $-14.65M | $-24.32M | $-76.46M | $-252.03M | $-9.17M | $-11.38M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.25% | 7.55% | 0.93% | -0.12% | 82.09% | 112.57% | 1.22% | 30.15% | 5.66% | 14.44% | 1.02% | 13.20% | 7.71% | 0.18% | 0.92% | 23.04% | 16.99% |
3 analysts predict BLUE's average Quarter EBITDA for Mar 23 to be $-91.26M, with a high of $-73.01M and a low of $-109.52M. This is -458.81% lower than bluebird bio's previous annual EBITDA (Dec 22) of $25.43M.
bluebird bio Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-71.73M | $-72.91M | $34.04M | $32.23M | $-76.52M | $-92.88M | $-123.96M | $101.69M | $-216.82M | $-241.70M | $-205.81M | $-199.87M | $-194.75M | $-21.46M | $-202.61M | $-223.35M | $-206.03M |
| Avg Forecast | $13.71M | $10.87M | $4.33M | $3.55M | $-15.33M | $4.32M | $-16.77M | $-40.04M | $-56.89M | $-70.54M | $-80.72M | $-86.05M | $-127.19M | $-129.52M | $-136.61M | $-92.03M | $-213.08M | $-216.41M | $-251.19M | $-98.42M | $-381.68M | $-307.48M | $-409.97M | $-201.71M | $-372.44M | $-382.72M | $-301.73M | $-221.31M | $-475.02M | $-446.36M |
| High Forecast | $13.71M | $10.87M | $4.33M | $3.55M | $-15.33M | $4.32M | $-16.77M | $-40.04M | $-56.89M | $-53.83M | $-80.72M | $-68.84M | $33.47M | $-129.52M | $-136.61M | $-73.62M | $-170.47M | $-216.41M | $-251.19M | $-78.74M | $-381.68M | $-307.48M | $-409.97M | $-161.36M | $-372.44M | $-382.72M | $-301.73M | $-177.04M | $-475.02M | $-446.36M |
| Low Forecast | $13.71M | $10.87M | $4.33M | $3.55M | $-15.33M | $4.32M | $-16.77M | $-40.04M | $-56.89M | $-85.39M | $-80.72M | $-103.25M | $-218.68M | $-129.52M | $-136.61M | $-110.43M | $-255.70M | $-216.41M | $-251.19M | $-118.11M | $-381.68M | $-307.48M | $-409.97M | $-242.05M | $-372.44M | $-382.72M | $-301.73M | $-265.57M | $-475.02M | $-446.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.55% | 0.53% | -0.37% | -0.15% | 0.35% | 0.37% | 1.26% | -0.27% | 0.71% | 0.59% | 1.02% | 0.54% | 0.51% | 0.07% | 0.92% | 0.47% | 0.46% |
bluebird bio's average Quarter net income forecast for Jun 23 is $-136.61M, with a range of $-136.61M to $-136.61M. BLUE's average Quarter net income forecast represents a -501.28% decrease compared to the company's last Quarter net income of $34.04M (Mar 23).
bluebird bio SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.70M | $40.35M | $37.35M | $30.71M | $33.40M | $36.69M | $36.11M | $-19.74M | $68.28M | $78.58M | $86.87M | $76.97M | $68.05M | $68.63M | $73.25M | $76.20M | $66.25M |
| Avg Forecast | $2.66B | $2.51B | $2.24B | $2.16B | $1.77B | $1.58B | $1.18B | $767.98M | $602.76M | $390.73M | $524.98M | $416.96M | $363.29M | $293.52M | $244.66M | $141.23M | $22.62M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| High Forecast | $2.66B | $2.51B | $2.24B | $2.16B | $1.77B | $1.58B | $1.18B | $767.98M | $602.76M | $449.78M | $524.99M | $424.13M | $446.83M | $294.41M | $244.66M | $141.23M | $22.62M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| Low Forecast | $2.66B | $2.51B | $2.24B | $2.16B | $1.77B | $1.58B | $1.18B | $767.98M | $602.76M | $272.85M | $524.98M | $409.78M | $251.68M | $292.64M | $244.66M | $141.23M | $22.62M | $23.25M | $17.84M | $4.06M | $110.03M | $805.36M | $352.41M | $249.99M | $317.17M | $526.51M | $1.66B | $164.07M | $198.49M | $246.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.14% | 0.16% | 0.26% | 1.36% | 1.44% | 2.06% | 8.90% | -0.18% | 0.08% | 0.22% | 0.35% | 0.24% | 0.13% | 0.04% | 0.45% | 0.38% | 0.27% |
bluebird bio's average Quarter SG&A projection for Dec 23 is $363.29M, based on 7 Wall Street analysts, with a range of $251.68M to $446.83M. The forecast indicates a 792.53% rise compared to BLUE last annual SG&A of $40.70M (Sep 23).
bluebird bio EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.66 | $-0.67 | $0.33 | $0.38 | $-0.94 | $-1.26 | $-1.68 | $1.40 | $-3.16 | $-3.58 | $-3.07 | $-3.01 | $-2.94 | $-0.36 | $-3.64 | $-4.04 | $-3.73 |
| Avg Forecast | $0.07 | $0.06 | $0.02 | $0.02 | $-0.08 | $0.02 | $-0.09 | $-0.21 | $-0.29 | $-0.36 | $-0.42 | $-0.44 | $-0.66 | $-0.67 | $-0.71 | $-0.37 | $-0.33 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| High Forecast | $0.07 | $0.06 | $0.02 | $0.02 | $-0.08 | $0.02 | $-0.09 | $-0.21 | $-0.29 | $-0.28 | $-0.42 | $-0.44 | $0.17 | $-0.67 | $-0.71 | $-0.37 | $-0.33 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| Low Forecast | $0.07 | $0.06 | $0.02 | $0.02 | $-0.08 | $0.02 | $-0.09 | $-0.21 | $-0.29 | $-0.44 | $-0.42 | $-0.44 | $-1.13 | $-0.67 | $-0.71 | $-0.37 | $-0.33 | $-1.12 | $-1.30 | $-1.45 | $-1.97 | $-1.59 | $-2.12 | $-1.95 | $-1.92 | $-1.98 | $-1.56 | $-2.62 | $-2.45 | $-2.30 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 0.95% | -0.89% | -1.16% | 0.84% | 0.97% | 1.16% | -0.71% | 1.99% | 1.69% | 1.57% | 1.57% | 1.49% | 0.23% | 1.39% | 1.65% | 1.62% |
According to 6 Wall Street analysts, bluebird bio's projected average Quarter EPS for Jun 23 is $-0.71, with a low estimate of $-0.71 and a high estimate of $-0.71. This represents a -313.70% decrease compared to BLUE previous annual EPS of $0.33 (Mar 23).
bluebird bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.63 | $70.00 | 11011.11% | Buy |
| BLUE | bluebird bio | $0.46 | $14.13 | 2971.74% | Hold |
| CVAC | CureVac | $2.71 | $29.00 | 970.11% | Buy |
| KPTI | Karyopharm Therapeutics | $0.93 | $7.33 | 688.17% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.73 | $21.86 | 486.06% | Buy |
| VIR | Vir Bio | $9.37 | $26.60 | 183.88% | Buy |
| MRSN | Mersana Therapeutics | $1.84 | $3.00 | 63.04% | Buy |
| VKTX | Viking Therapeutics | $63.14 | $100.50 | 59.17% | Buy |
| YMAB | Y-mAbs Therapeutics | $14.87 | $20.50 | 37.86% | Buy |
| SRPT | Sarepta Therapeutics | $123.07 | $169.63 | 37.83% | Buy |
| TVTX | Travere Therapeutics | $18.10 | $21.38 | 18.12% | Buy |
| PTCT | PTC Therapeutics | $40.39 | $46.50 | 15.13% | Hold |
| KRYS | Krystal Biotech | $170.85 | $191.00 | 11.79% | Buy |
| AGIO | Agios Pharmaceuticals | $44.83 | $48.71 | 8.65% | Buy |
| MDGL | Madrigal Pharmaceuticals | $331.32 | $315.75 | -4.70% | Buy |
BLUE Forecast FAQ
Is bluebird bio a good buy?
No, according to 4 Wall Street analysts, bluebird bio (BLUE) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 25.00% of BLUE's total ratings.
What is BLUE's price target?
bluebird bio (BLUE) average price target is $14.13 with a range of $5 to $25, implying a 2951.84% from its last price of $0.463. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will bluebird bio stock go up soon?
According to Wall Street analysts' prediction for BLUE stock, the company can go up by 2951.84% (from the last price of $0.463 to the average price target of $14.13), up by 5299.57% based on the highest stock price target, and up by 979.91% based on the lowest stock price target.
Can bluebird bio stock reach $1?
BLUE's average twelve months analyst stock price target of $14.13 supports the claim that bluebird bio can reach $1 in the near future.
What are bluebird bio's analysts' financial forecasts?
bluebird bio's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $244.95M (high $244.95M, low $244.95M), average EBITDA is $-245M (high $-245M, low $-245M), average net income is $-67.822M (high $-67.822M, low $-67.822M), average SG&A $5.3B (high $5.3B, low $5.3B), and average EPS is $-0.35 (high $-0.35, low $-0.35). BLUE's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $442.07M (high $442.07M, low $442.07M), average EBITDA is $-442M (high $-442M, low $-442M), average net income is $32.46M (high $32.46M, low $32.46M), average SG&A $9.57B (high $9.57B, low $9.57B), and average EPS is $0.168 (high $0.168, low $0.168).
Did the BLUE's actual financial results beat the analysts' financial forecasts?
Based on bluebird bio's last annual report (Dec 2022), the company's revenue was $3.6M, beating the average analysts forecast of $3.13M by 14.88%. Apple's EBITDA was $-277M, missing the average prediction of $-306M by -9.30%. The company's net income was $-267M, missing the average estimation of $-779M by -65.78%. Apple's SG&A was $136.91M, beating the average forecast of $67.77M by 102.01%. Lastly, the company's EPS was $-3.39, missing the average prediction of $-4.188 by -19.05%. In terms of the last quarterly report (Sep 2023), bluebird bio's revenue was $12.39M, missing the average analysts' forecast of $13.56M by -8.62%. The company's EBITDA was $-84.729M, beating the average prediction of $-13.56M by 524.83%. bluebird bio's net income was $-71.731M, missing the average estimation of $-130M by -44.62%. The company's SG&A was $40.7M, missing the average forecast of $293.52M by -86.13%. Lastly, the company's EPS was $-0.66, missing the average prediction of $-0.669 by -1.29%